Bicycle Therapeutics plc (BCYC)
Market Cap | 1.01B |
Revenue (ttm) | 41.61M |
Net Income (ttm) | -168.16M |
Shares Out | 41.11M |
EPS (ttm) | -4.42 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 79,988 |
Open | 24.56 |
Previous Close | 24.44 |
Day's Range | 24.33 - 25.00 |
52-Week Range | 12.54 - 27.24 |
Beta | 0.93 |
Analysts | Strong Buy |
Price Target | 47.25 (+92.78%) |
Earnings Date | Aug 5, 2024 |
About BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeti... [Read more]
Financial Performance
In 2023, BCYC's revenue was $26.98 million, an increase of 86.52% compared to the previous year's $14.46 million. Losses were -$180.66 million, 60.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BCYC stock is "Strong Buy." The 12-month stock price forecast is $47.25, which is an increase of 92.78% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/y/a/press16-2536175.jpg)
Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...
![](https://cdn.snapi.dev/images/v1/o/t/conf1-2458580.jpg)
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...
![](https://cdn.snapi.dev/images/v1/c/b/conf13-2446542.jpg)
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...
![](https://cdn.snapi.dev/images/v1/2/f/press12-2445106.jpg)
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc...
![](https://cdn.snapi.dev/images/v1/o/f/press5-2405584.jpg)
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...
![](https://cdn.snapi.dev/images/v1/e/i/press15-2388330.jpg)
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...
![](https://cdn.snapi.dev/images/v1/y/m/press11-2351605.jpg)
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...
![](https://cdn.snapi.dev/images/v1/k/u/conf7-2309698.jpg)
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...
![](https://cdn.snapi.dev/images/v1/w/z/press5-2283141.jpg)
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bi...
![](https://cdn.snapi.dev/images/v1/m/e/press20-2264077.jpg)
Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...
![](https://cdn.snapi.dev/images/v1/t/1/press1-2195962.jpg)
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p...
![](https://cdn.snapi.dev/images/v1/c/u/press1-2177469.jpg)
Bicycle Therapeutics to Host R&D Day on December 14
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...
![](https://cdn.snapi.dev/images/v1/p/a/press17-2135543.jpg)
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...
![](https://cdn.snapi.dev/images/v1/j/f/press4-2110616.jpg)
Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p...
![](https://cdn.snapi.dev/images/v1/d/j/press15-2110367.jpg)
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-...
![](https://cdn.snapi.dev/images/v1/n/x/press7-2057154.jpg)
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p...
![](https://cdn.snapi.dev/images/v1/f/z/conf3-2048924.jpg)
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic p...
![](https://cdn.snapi.dev/images/v1/t/c/press9-2003980.jpg)
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...
![](https://cdn.snapi.dev/images/v1/8/p/press11-1975438.jpg)
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...
![](https://cdn.snapi.dev/images/v1/e/r/press8-1969278.jpg)
Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...
![](https://cdn.snapi.dev/images/v1/r/v/press5-1968943.jpg)
Bicycle Therapeutics Announces Proposed $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...
![](https://cdn.snapi.dev/images/v1/e/4/press9-1945578.jpg)
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...
![](https://cdn.snapi.dev/images/v1/z/f/press10-1931498.jpg)
Bicycle Therapeutics to Participate in the TD Cowen Radiopharmaceutical Innovation Summit
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl...
![](https://cdn.snapi.dev/images/v1/3/u/press13-1913818.jpg)
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli...
![](https://cdn.snapi.dev/images/v1/t/x/press18-1884679.jpg)
Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
CAMBRIDGE, England & BOSTON & PARIS--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results. Bicycle is pioneer...